MorphoSys AG Reports Outcome of Annual General Meeting 2016
(Thomson Reuters ONE) -
MorphoSys AG /
MorphoSys AG Reports Outcome of Annual General Meeting 2016
. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) reported the outcome of
the Company's Annual General Meeting, which took place in Munich on Thursday,
June 2, 2016. The shareholders of MorphoSys AG approved the following management
proposals put to vote at the meeting:
* The appropriation of the accumulated income for the 2015 financial year
* The discharge of the members of the Management and Supervisory Boards with
respect to the 2015 financial year
* The appointment of PricewaterhouseCoopers AG as auditor for the 2016
financial year
* Resolution on the cancelation of Conditional Capital 2003-II; change in the
Articles of Association
* Resolution on the creation of a new Conditional Capital 2016-I;
authorization of the Management Board to issue convertible bonds and/or
bonds with warrants with the option to exclude subscription rights; change
in the Articles of Association
* Resolution on the creation of Conditional Capital 2016-III and the
authorization to grant subscription rights to members of the Management
Board of MorphoSys AG, to members of management bodies of affiliated
companies in Germany and abroad as well as to selected executives of
MorphoSys AG and affiliated companies in Germany and abroad (Stock Option
Plan 2016); change in the Articles of Association.
The resolution on the creation of Conditional Capital 2016-II and the
authorization to grant subscription rights to members of the Management Board of
MorphoSys AG, to members of management bodies of affiliated companies in Germany
and abroad as well as to selected executives of MorphoSys AG and of affiliated
companies in Germany and abroad (Performance Share Plan 2016) (change in the
Articles of Association) were supported by 72.25 % but did not receive the
required 75 % majority of the represented share capital. At the Annual General
Meeting 2016 of MorphoSys AG, 54.1 % of the voting shares were represented.
"On behalf of the Management Board and the Company, I would like to thank our
shareholders for their continued support and trust," commented Dr. Simon
Moroney, Chief Executive Officer of MorphoSys AG.
More information on the Company's Annual General Meeting including the voting
results on all agenda items can be found on http://www.morphosys.com/agm.
About MorphoSys
MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic
pipeline of more than 100 human antibody drug candidates for the treatment of
cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With
its ongoing commitment to new antibody technology and drug development,
MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is
listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates
about MorphoSys, visit http://www.morphosys.com.
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla®, Ylanthia®,
100 billion high potentials®, Slonomics®, Lanthio Pharma® and LanthioPep® are
registered trademarks of the MorphoSys Group.
This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and involve
risks and uncertainties. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward-looking statements as
far as the wording of the relevant press release is concerned.
For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Jochen Orlowski
Associate Director Corporate Communications & IR
Alexandra Goller
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-404
investors(at)morphosys.com
Media Release (PDF):
http://hugin.info/130295/R/2017565/748650.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via GlobeNewswire
[HUG#2017565]
Unternehmensinformation / Kurzprofil:
Datum: 02.06.2016 - 15:08 Uhr
Sprache: Deutsch
News-ID 475371
Anzahl Zeichen: 5558
contact information:
Town:
Martinsried / Munich
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 309 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"MorphoSys AG Reports Outcome of Annual General Meeting 2016"
steht unter der journalistisch-redaktionellen Verantwortung von
MorphoSys AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
